Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 04:00PM ET
1.33
Dollar change
-0.03
Percentage change
-2.57
%
Index- P/E- EPS (ttm)-0.16 Insider Own52.17% Shs Outstand12.84M Perf Week-13.96%
Market Cap17.01M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.14M Perf Month-
Income-2.01M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-0.21 P/B- EPS next Y- ROA-199.80% Short Interest- Perf Year-
Cash/sh0.00 P/C850.65 EPS next 5Y- ROE- 52W Range1.22 - 4.00 Perf YTD-49.04%
Dividend Est.- P/FCF567.10 EPS past 5Y- ROI- 52W High-66.87% Beta-
Dividend TTM- Quick Ratio0.01 Sales past 5Y0.00% Gross Margin- 52W Low8.61% ATR (14)0.42
Dividend Ex-Date- Current Ratio0.01 EPS Y/Y TTM-147.15% Oper. Margin0.00% RSI (14)- Volatility15.59% -
Employees3 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-7.07% Payout- Rel Volume0.14 Prev Close1.36
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume341.93K Price1.33
SMA20-30.01% SMA50-30.01% SMA200-30.01% Trades Volume48,304 Change-2.57%
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.